Bristol-Myers Squibb (United States)

A comparative evaluation of Bayesian model-assisted two-stage designs for Phase I/II clinical trials

The primary goal of a two-stage Phase I/II trial is to identify the optimal dose for the following large-scale Phase III trial. Conventional Phase I designs focus on the maximum tolerated dose (MTD), assuming that efficacy increases monotonically with dose. However, this assumpti...

Exploring transcriptomic and genomic latent variable correction approaches in differential expression analysis

Abstract Background Differential expression analysis is a central tool for studying the biological processes altered in human diseases via transcriptomic signatures. However, transcriptomic datasets are systematically confounded by latent variables from two distinct sources: unme...

Left Ventricular Structural, Physiological, and Transcriptomic Abnormalities in a Novel Porcine Hypertrophic Cardiomyopathy Model

sensitivity. The cardiac myosin inhibitor MYK-581 reduced hypercontractility and improved diastolic function. Data from this large animal genetic model of HCM strengthen the mechanistic link between genetic variants and in vivo phenotypes and elucidate the mechanisms of myofilame...

Histology resolved proteomic characterization of the triple negative breast cancer tumor immune microenvironment

Treatment options for the highly aggressive triple-negative breast cancer (TNBC) subtype remain limited, though the immune microenvironment represents a promising therapeutic target. We conducted a histology resolved tumor microenvironment analysis of TNBC by employing deep quant...

Toward actionable biomarkers in psychiatry: a collaborative roadmap for precision clinical trials. An ACNP position paper

Abstract Psychiatric drug development remains constrained by diagnostic heterogeneity, insufficient and inconsistent drug response, high placebo response rates, and the absence of validated biomarkers that can reliably guide patient stratification, trial design, and regulatory de...

A single-cell atlas of large B cell lymphomas reveals distinct malignant archetypes predictive of clinical outcomes

Large B cell lymphomas (LBCLs) exhibit significant heterogeneity which leads to disparate treatment response, with up to 40% of patients developing refractory disease or relapsing within the first two years. To understand the cellular and molecular basis of this heterogeneity, we...

Discovery and Characterization of a Novel Ligand-Binding Site in UFC1 Using Sulfa- and Sulfonate-Based Compounds

Abstract UFMylation is an important biological process where proteins are post-translationally modified via the covalent attachment of the ubiquitin-like modifier (UBL), ubiquitin-fold modifier-1 (UFM1). UFMylation is analogous to ubiquitination, occurring via the transfer of UFM...

Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event

BackgroundPatients are at increased risk for recurrent ischemic events after an acute coronary syndrome event. Milvexian, an oral factor XIa inhibitor, may reduce the risk of major adverse clinical events with minimal bleeding risk. MethodsIn this phase 3, randomized, placebo-con...

Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis

BACKGROUND: Nivolumab plus ipilimumab-based therapies have shown long-term, durable clinical benefit in patients with metastatic non-small cell lung cancer (NSCLC), including those with tumor programmed death-ligand 1 (PD-L1) expression < 1%, a population with high unmet need. He...

Evolution of treatment distribution and patient characteristics of muscle invasive bladder cancer patients: results from two multi-national real-world surveys

To describe the real-world clinical characteristics and treatment distribution of patients with muscle-invasive bladder cancer (MIBC), and to discuss how these patterns have evolved over time. Data were drawn two separate cohorts of the Adelphi Muscle Invasive Urothelial Cancer D...